• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Aminoquinolines and derivatives

Recent Advances in the Study of 3-Bromoquinolin-7-amine (CAS: 1344046-07-6) in Chemical Biology and Pharmaceutical Research

3-Bromoquinolin-7-amine (CAS: 1344046-07-6) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have highlighted its potential as a key intermediate in the synthesis of novel therapeutic agents, particularly in the fields of oncology and infectious diseases. This research brief aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

Recent literature has demonstrated that 3-Bromoquinolin-7-amine serves as a crucial building block in the synthesis of quinoline-based compounds, which are known for their broad-spectrum biological activities. A study published in the Journal of Medicinal Chemistry (2023) detailed the efficient synthesis of 3-Bromoquinolin-7-amine via a palladium-catalyzed cross-coupling reaction, achieving high yields and excellent purity. This methodological advancement has paved the way for the scalable production of this compound, facilitating its use in high-throughput screening and drug development pipelines.

In the context of biological activity, 3-Bromoquinolin-7-amine has shown promising results as a precursor for the development of kinase inhibitors. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) reported that derivatives of this compound exhibited potent inhibitory effects against several cancer-related kinases, including EGFR and BRAF. The researchers attributed this activity to the bromine substituent at the 3-position, which enhances the compound's binding affinity to the kinase active site. These findings suggest that 3-Bromoquinolin-7-amine could play a pivotal role in the design of next-generation targeted cancer therapies.

Beyond oncology, 3-Bromoquinolin-7-amine has also been investigated for its potential in combating infectious diseases. A 2023 study in Antimicrobial Agents and Chemotherapy demonstrated that quinoline derivatives synthesized from this compound exhibited significant activity against drug-resistant strains of Mycobacterium tuberculosis. The researchers highlighted the compound's ability to disrupt bacterial cell wall synthesis, offering a novel mechanism of action that could circumvent existing resistance mechanisms. This discovery underscores the compound's potential as a scaffold for developing new anti-infective agents.

Despite these promising developments, challenges remain in the optimization of 3-Bromoquinolin-7-amine-based therapeutics. Recent pharmacokinetic studies have identified issues related to the compound's metabolic stability and bioavailability, which may limit its clinical applicability. However, ongoing research efforts are addressing these limitations through structural modifications and formulation strategies. For instance, a 2024 study in the European Journal of Pharmaceutical Sciences reported significant improvements in the oral bioavailability of 3-Bromoquinolin-7-amine derivatives through the incorporation of prodrug moieties.

In conclusion, 3-Bromoquinolin-7-amine (CAS: 1344046-07-6) represents a valuable chemical entity with diverse applications in drug discovery. Recent advances in its synthesis, biological evaluation, and structural optimization have positioned it as a promising candidate for the development of novel therapeutics. Future research should focus on further elucidating its mechanism of action, improving its pharmacokinetic properties, and expanding its therapeutic potential to other disease areas. The continued exploration of this compound is expected to yield significant contributions to the field of chemical biology and pharmaceutical sciences.

• 65340-75-2(4-Amino-8-bromoquinoline)
• 7101-96-4(3-Bromoquinolin-6-amine)
• 116632-58-7(8-Bromoquinolin-5-amine)
• 214279-28-4(1H-Indol-6-amine,7-bromo-)
• 351458-46-3(4-bromoisoquinolin-8-amine)
• 65340-74-1(4-Amino-7-bromoquinoline)
• 525590-24-3(3-Bromo-1H-indol-5-amine)
• 36825-36-2(3-bromoquinolin-4-amine)
• 65340-73-0(6-bromoquinolin-4-amine)
• 157996-59-3(9-Acridinamine,2-bromo-)